Omeros Corporation Stock News

LOS ANGELES, Oct. 7, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Omeros Corporation ("O

LOS ANGELES--(BUSINESS WIRE)---- $OMER #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on

BENSALEM, Pa.--(BUSINESS WIRE)---- $OMER #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER) inve

LOS ANGELES--(BUSINESS WIRE)---- $OMER #OMER--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation.

LOS ANGELES--(BUSINESS WIRE)---- $OMER #OMER--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation.

New York, New York--(Newsfile Corp. - October 1, 2021) -  Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors

The stock price of Omeros Corporation (Nasdaq: OMER) fell by over 39% during intraday trading today. This is why it happened.

Today, some rather unfortunate news has come to light regarding one of Omeros' prospective drugs, taking OMER stock 40% lower. The post OMER Stock: Why Little-Known Omeros Is Absolutely Plunging Today

The U.S. FDA notified Omeros Corporation (NASDAQ: OMER) that it identified deficiencies in the company's marketing application for Narsoplimab, Omeros disclosed in a press release this morning.   Sha

The narsoplimab program hasn't proceeded as swimmingly as investors thought.

Investors need to pay close attention to Omeros (OMER) stock based on the movements in the options market lately.

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the U.S. Food and Drug Administration (FDA) notified the company that, as part of FDA's ongoing review of the company'

The biotech stock was part of a larger Wall Street sell-off.

Omeros: The Prize Is Nigh (Again)

Omeros Corporation's (OMER) CEO Greg Demopulos on Q2 2021 Results - Earnings Call Transcript